Watch Robert Thong’s Presentation at Investival Showcase – November 18, 2024
In this compelling presentation at the Investival Showcase, held on November 18, 2024, our CEO, Robert Thong, delves into MultiOmic Health‘s groundbreaking approach to advancing precision medicine for metabolic-syndrome-related conditions, with a particular focus on diabetic kidney disease (DKD). Robert outlines the significant progress we’ve made in patient endotype discovery, identifying previously unpublished clinical phenotypes with distinct omics signatures that map the unique disease journeys of DKD patients.
He also introduces our cutting-edge Patient-Stratifying Biomarkers (PSBs), which leverage AI-enabled algorithms to predict DKD endotypes from baseline proteomics, transforming how we approach patient selection for clinical trials. Looking ahead, Robert discusses the milestones we plan to achieve in the next 12 months, including the deployment of these biomarkers to enrich pharma clinical trials and the acceleration of our therapeutic programs aimed at specific patient subpopulations.
Watch the video below to gain insight into how MultiOmic Health is reshaping the future of precision medicine, making personalized treatments more accessible and effective for metabolic disease patients.
